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Cyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid fol-
licles, a condition that has been called “in situ mantle cell lymphoma”. The clinical significance
of this lesion remains uncertain. 
Design and Methods
The clinical and pathological characteristics, including SOX11 expression, of 23 cases initially
diagnosed as in situ mantle cell lymphoma were studied. 
Results
Seventeen of the 23 cases fulfilled the criteria for in situ mantle cell lymphoma.  In most cases,
the lesions were incidental findings in reactive lymph nodes. The t(11;14) was detected in all
eight cases examined. SOX11 was positive in seven of 16 cases (44%). Five cases were associ-
ated with other small B-cell lymphomas. In two cases, both SOX11-positive, the in situ mantle
cell lymphoma lesions were discovered after the diagnosis of overt lymphoma; one 4 years ear-
lier, and one 3 years later. Twelve of the remaining 15 patients had a follow-up of at least 1 year
(median 2 years; range, 1-19.5), of whom 11 showed no evidence of progression, including
seven who were not treated. Only one of 12 patients with an in situ mantle cell lymphoma
lesion and no diagnosis of mantle cell lymphoma at the time developed an overt lymphoma, 4
years later; this case was also SOX11-positive. The six remaining cases were diagnosed as man-
tle cell lymphoma with a mantle zone pattern. Five were SOX11-positive and four of them
were associated with lymphoma without a mantle zone pattern.
Conclusions
In situ mantle cell lymphoma lesions are usually an incidental finding with a very indolent
behavior. These cases must be distinguished from mantle cell lymphoma with a mantle zone
pattern and overt mantle cell lymphoma because they may not require therapeutic interven-
tion. 
Key words: in situ mantle cell lymphoma, in situ involvement by mantle cell-lymphoma-like
cells, indolent behavior.
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Introduction
Mantle cell lymphoma (MCL) is a B-cell neoplasm that
usually carries the t(11;14)(q13;q32) translocation and con-
stitutively overexpresses cyclin D1.1 Most patients present
in an advanced stage, with generalized lymphadenopathy,
and frequent involvement of extranodal sites and peripheral
blood. The clinical evolution is relatively aggressive with a
poor response to conventional therapeutic regimens, fre-
quent relapses and a median overall survival of 3-5 years.
This biological behavior has led to the recommendation for
early treatment, usually with intensive therapeutic regi-
mens that may include hematopoietic stem cell transplanta-
tion.2 However, recent clinical and pathological observa-
tions have recognized subsets of patients whose disease has
an indolent clinical behavior and who may not need imme-
diate treatment.3-6
It is well-recognized that MCL has a wide spectrum of
growth patterns.  Most cases have a vaguely nodular and/or
diffuse growth pattern, very rare cases have a follicular
growth pattern, and a larger minority has a mantle zone
growth pattern in which the lymphoma grows as an
expanded ring around reactive germinal centers. Although
controversial, one study suggested that a mantle zone
growth pattern was associated with a better prognosis.7
More recently, isolated reports have described cases with
cyclin D1-positive MCL-like cells restricted to the mantle
zone of hyperplastic follicles in otherwise reactive lymph
nodes.8-14 The restricted distribution of the atypical cells sug-
gests that these lesions may represent an early step in the
development of MCL, and the process has been termed “in
situ MCL”. A similar phenomenon with a restricted distribu-
tion of follicular lymphoma-like cells with BCL2 rearrange-
ment and overexpression within reactive germinal centers
has been termed follicular lymphoma in situ (FLIS).15,16
However, it is not known whether either FLIS or “in situ”
MCL represent true precursor lesions that will inevitably
progress to overt lymphoma, or are simply incidental find-
ings with a low likelihood of progression, analogous to
monoclonal gammopathy of unknown significance or mon-
oclonal B-cell lymphocytosis. Thus, the malignant potential
of these lesions and their clinical and biological significance
are not well known. In fact, some patients have been fol-
lowed for a long time without antineoplastic therapy9,10
whereas others with the same histological pattern have
been treated with conventional therapies including inten-
sive chemotherapy and stem cell transplantation.13
SOX11, a neural transcription factor involved in tissue
remodeling during embryogenesis, is a highly sensitive bio-
marker of MCL since it is expressed in virtually all MCL,
including cyclin D1-negative cases, but is not expressed in
any other lymphoid neoplasm with the exception of lym-
phoblastic lymphoma, some Burkitt lymphomas and T-
prolymphocytic leukemia.17-20 SOX11 negativity has been
recently associated with a subset of MCL with a very indo-
lent behavior, non-nodal presentation, hypermutated IGHV
and simple karyotypes suggesting that this lack of expres-
sion may help to identify a particular clinical and biological
subtype of MCL.6 The expression of SOX11 in early lesions
of MCL and tumors with a mantle zone growth pattern has
not been investigated and it is not, therefore, known
whether its expression is an early or later event in the devel-
opment of these tumors. 
In this study we investigated a large series of cases previ-
ously diagnosed as “in situMCL”, to define their clinical and
pathological significance, their distinction from MCL with a
mantle zone growth pattern, and the potential value of
SOX11 in the characterization of these lesions.
Design and methods 
Case selection
We identified 23 cases initially diagnosed as “in situ MCL”
lesions over a period of 8 years (2003-2010);  as cited in Table 1,9-14
seven of these cases have been published previously. The follow-
ing sites participated in the study: National Cancer Institute,
Bethesda, MD, USA (6 cases); Hospital Clínic Barcelona, Spain (3
cases); Oslo University Hospital, Oslo, Norway (3 cases);
Hammersmith Hospital, London, UK (2 cases); University of
Pittsburgh, Pittsburgh, PA, USA (2 cases); Stanford University
Medical Center, Stanford, CA, USA (2 cases); Hospital del Mar,
Barcelona, Spain (1 case); Hospital of the University of
Pennsylvania, Philadelphia, PA, USA (1 case); CHU Purpan,
Toulouse, France (1 case); Brigham & Women Hospital, Boston,
MA, USA (1 case) and Massachusetts General Hospital, Boston,
MA, USA (1 case). This study was approved by the Institutional
Review Board of the participating institutions, where required. All
23 cases were detected on the basis of a restricted location of cyclin
D1-positive cells within the mantle zones of reactive follicles.
Clinical information and follow-up from these patients were
obtained from the referring pathologists and/or clinicians to the
extent possible. The follow-up of the previously published patients
was updated and new histological sections were obtained for addi-
tional studies. While the cases were originally diagnosed by the
contributing pathologists, all cases were subsequently reviewed by
two of the authors (AC-C, EC).  In addition, we collected 100 con-
secutive lymph node biopsies from the Hospital Clinic of
Barcelona diagnosed as follicular lymphoid hyperplasia in patients
older than 40 years. None of these patients had a previous or
simultaneous diagnosis of a lymphoid neoplasm. 
Histological and immunohistochemical studies 
Paraffin-embedded tissue was available from the diagnostic
biopsies. Immunohistochemical stains were performed in the 23
cases with a previous diagnosis of “in situ MCL” lesions with a
panel of pre-diluted antibodies from DAKO (Glostrup, Denmark)
including CD20 (clone L26), IgD (polyclonal), CD23 (SP23), CD5
(clone 4C7), cyclin D1 (clone SP4) and BCL2 (clone 123). We also
used CD3 (clone PS1, Novocastra, Newcastle, UK) and SOX11
(Atlas Antibodies, Stockholm, Sweden). The one hundred reactive
lymph nodes were stained with cyclin D1 and BCL2. SOX11 stain-
ing was performed as previously described20 using a heat-induced
retrieval with ER2 BondMax buffer solution for 15 min, a horserad-
ish-peroxidase–linked polymer for 8 min (Define; Vision
Biosystems) and 5′-3′ diaminobenzidine for 10 min. Staining with
the routine panel of the remaining antibodies was performed using
automated immunostainers (Autostainer Link, DAKO or
Benchmark, Ventana Medical Systems, Tucson, AZ, USA).
Genetic studies
Classical G-banded cytogenetic studies from peripheral blood or
tissue samples were available in four cases. Fluorescence in situ
hybridization (FISH) studies were performed in eight cases using a
standard procedure previously described21 and dual-fusion DNA
probes for IGH@-CCND1 (Abbot Molecular, Abbot Park, IL,
USA). One additional case (case 8) was studied with FISH and
simultaneous cyclin D1 immunofluorescence using a modification
of the immuno-FISH protocol described by Cook et al.22 with a
dual color, dual fusion probe for t(11;14)(q13;q32) (Vysis, Downers
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Grove, IL, USA) and cyclin D1 antibody (clone SP4) on paraffin
sections. Two hundred cells specifically identified by nuclear cyclin
D1 staining under a 4’-6’-diamidino-2-phenylindole filter were
analyzed.  Nuclei were scored as positive if at least one fusion sig-
nal was present or as negative in all other patterns. Paraffin sec-
tions of tonsils were used as negative controls.  
Results
Histopathology and immunohistochemical studies 
We identified 23 cases initially diagnosed as “in situMCL”
lesions based on the restriction of cyclin D1-positive cells to
the mantle zone of reactive follicles. The main clinical and
pathological features of these cases are summarized in
Tables 1-3.  The distribution and expansion of the cyclin
D1-positive cells was variable among the cases and upon
review we could distinguish two major patterns; one we
refer to as an “in situMCL” pattern and the other was des-
ignated as a mantle zone pattern.
The “in situ MCL” pattern was identified in 17 cases, in
which the global architecture of the lymphoid tissue was
preserved and the reactive follicles were mainly distributed
in the cortical areas with an evident paracortical space
among them. The mantle zones of these follicles were usu-
ally not expanded and cyclin D1-positive cells were restrict-
ed to the mantle zones with only scattered cells in the inter-
follicular areas. In some cases the mantle zone was expand-
ed but the cyclin D1-positive cells were restricted only to a
few layers and not all follicles contained these cells (Figure
1A-B). In general, cyclin D1-positive cells tended to accu-
mulate in the inner mantle zone but in two cases they were
localized at the periphery of the mantle zone and in one
case they extended focally into the germinal centers (Figure
1C-E). Similar features were found with involvement local-
ized to otherwise unremarkable mantle zones in lymphoid
tissue at extranodal sites as well.  
Six of the 23 cases showed a greater expansion of the
cyclin D1-positive cells and were designated as MCL with
a mantle zone growth pattern. In these cases the architec-
ture of the lymphoid tissue was still largely preserved but
with focal effacement, more numerous, crowded, involved
follicles and marked reduction of the interfollicular space.
The mantle zones were usually expanded and the cyclin
D1-positive cells were densely packed replacing virtually
all the mantle zone cells. Focal extension of clusters of
cyclin D1-positive cells into the interfollicular areas was
seen and the mantle zones of different follicles merged
focally (Figure 2).
CD5 was difficult to evaluate in the 17 cases with an “in
situMCL” pattern as they had only few cyclin D1-positive
cells. However, in eight cases, comparison between cyclin
D1, CD5 and CD3 staining revealed that the cyclin D1-pos-
itive cells were CD5-negative. Two of these cases also had
clonal tumor cells in the peripheral blood and the flow
cytometry study confirmed the CD5 negativity in both. In
one of them a flow cytometry study performed during fol-
low-up 12 years after the diagnosis showed that the clonal
a. Carvajal-Cuenca et al.
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Figure 1. In situ MCL. (A) The global architec-
ture of the lymph node is preserved (hema-
toxylin-eosin stain, Olympus BX51, magnifica-
tion x12.5). (B) Cyclin D1-positive cells are
restricted to the mantle zones, which are not
expanded (cyclin D1 stain, Olympus BX51,
magnification x12.5). (C-E) “In-situ MCL”
growth patterns. (C) Few cyclin D1-positive
cells accumulate in the inner layer of the
mantle zone (cyclin D1 stain, Olympus BX51,
magnification x200). (D) Cyclin D1-positive
cells that replace almost all the cells in the
mantle zone, but the mantle zone is not
expanded (cyclin D1 stain, Olympus BX51,
magnification x100). (E) Cyclin D1-positive
cells at the periphery of the mantle zone
(cyclin D1 stain, Olympus BX51, magnification
x200). (F, G) FISH and simultaneous cyclin D1
immunofluorescence in case 8. (F) Normal
cell with negative nuclear immunofluores-
cence for cyclin D1; FISH using a dual-fusion
probe for t(11;14) shows two red and two
green signals corresponding to the presence
of CCND1 and IGH genes, respectively, without
rearrangement. (G) Cyclin D1 expression is
shown by the blue nuclear immunofluores-
cence and the presence of the t(11;14) by two
yellow fusion signals (arrows) in the same
cell. (Olympus BX51, magnification x100,
acquisition software Applied Imaging
Cytovision FISH, size modified after acquisi-
tion with Adobe Photoshop).
population had become CD5-positive.  
SOX11 was positive in seven of 16 (44%) cases with an
“in situ MCL” pattern in which sections were available for
staining, and in five of the six (83%) MCL with a mantle
zone growth pattern. SOX11 showed a nuclear staining
pattern and correlated well with the distribution of the
cyclin D1-positive cells. In addition to the cyclin D1-posi-
tive cells, endothelial and follicular dendritic cells showed
nuclear positivity and were used as internal controls (Figure
3).
A composite lymphoid neoplasm was found in five of the
17 cases with an “in situMCL” pattern (34%): chronic lym-
phocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) in two cases, marginal zone lymphoma in two
cases (one nodal and one extranodal) and follicular lym-
phoma grade 1-2 with a FLIS component in one case. The
CLL diagnosis had been previously established in the two
patients with CLL; the “in situMCL” lesion was only recog-
nized in subsequent biopsies performed based on an
enlarged lymph node and oropharyngeal mass, respectively.
Two different B-cell clones were observed by a flow cytom-
etry study of peripheral blood in one of these cases (Table
1). Both CLL had a classical phenotype. The composite lym-
phomas in the other three patients were apparently local-
ized after computed tomography studies (cases 4 and 6),
multiple gastrointestinal biopsies (case 5), bone marrow
(cases 5 and 17) and peripheral blood (cases 4, 5, 6 and 17)
examination. One additional patient had simultaneous
Castleman disease of hyaline-vascular type. SOX11 was
studied in five of these cases and was negative in four
(80%). The SOX11-positive case was associated with
CLL/SLL. All the associated lymphoid neoplasms were
SOX11-negative.
To explore the frequency of occurrence of incidental “in
situMCL” lesions in reactive lymph nodes and to compare
it to the frequency of detection of FLIS, we stained 100 con-
secutive lymph nodes with follicular hyperplasia for BCL2
and cyclin D1. Two cases showed scattered follicles with
strong BCL2 staining of the germinal center cells correspon-
ding to what has been termed FLIS. These cases included a
mesenteric lymph node obtained as part of the diagnostic
study of a recurrent gastric adenocarcinoma in a 49-year old
In situ mantle cell lymphoma
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Figure 2. MCL, mantle zone growth pat-
tern. (A) Mantle zones are expanded and
merge (hematoxylin-eosin stain, Olympus
BX51, magnification x40). (B) Cyclin D1-
positive cells replace virtually all the man-
tle zones of reactive follicles (cyclin D1
stain, Olympus BX51, magnification x40).
Figure 3. (A, B) In situ MCL lesion, SOX11-
positive case. The distribution of the
SOX11-positive cells (A) correlates well
with that of the cyclin D1-positive cells (B)
(SOX11 stain (A), cyclin D1 stain (B),
Olympus BX51, magnification x200). (C, D)
“In situ” MCL lesion, SOX11-negative case.
SOX11 is negative in the mantle zone cells
(C), while cyclin D1-positive cells are seen
(D). Note the follicular dendritic cells and
the endothelial cells as positive internal
controls for SOX11 stain (C) (SOX11 stain
(C), cyclin D1 stain (D), Olympus BX51,
magnification x200).
female and an inguinal lymph node biopsy performed as
part of a left inguinal hernioplasty in a 61-year old male.
None of the 100 cases had cyclin D1-positive cells in the
mantle zones.
Genetics
The t(11;14) was demonstrated in nine of nine cases with
an “in situMCL” pattern of cyclin D1-positive cells by con-
ventional cytogenetics of lymph node or peripheral blood
samples (3 cases) and/or by FISH studies (8 cases). In one of
these cases we performed a FISH study with simultaneous
cyclin D1 immunofluorescence and demonstrated the pres-
ence of the t(11;14) in cyclin D1-positive cells (Figure 1 F-G).
The t(11;14) was identified in 64-95% of the cells analyzed
(mean 84%) in the case sections compared to 2-4% (mean
3%) in the tonsil control sections. The t(11;14) was detected
in two SOX11-positive and in seven SOX11-negative cases
with an “in situ MCL” pattern. The t(11;14) was also con-
firmed by conventional cytogenetics or FISH in two of two
MCL with a mantle zone growth pattern, one SOX11-pos-
itive and the other SOX11-negative.
Clinical features associated with “in situ mantle
cell lymphoma” lesions
The patients with “in-situMCL” lesions were nine males
and eight females with a median age of 66 years (range,
a. Carvajal-Cuenca et al.
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Table 1. Clinical features, follow-up and histopathological findings in in situ MCL lesions.
Case Sex Age Site Other Biopsy BM PB Management Follow-up Status CD5 Composite Other
no of biopsy sites indication lymphoma associated
pathology
SOX11-negative cases 
19 F 29 LN, inguinal LN,  Multiple Yes Yes W&W 19.5 y AWD (PB) -*
axillary LN (2.6 109/L)
2 F 42 LN, cervical Enlarged LN, No No W&W 1y AND - Breast cancer
history of CA
310 F 70 LN, sub-mandibular Enlarged LN Yes Yes W&W 12y AWD (PB) - Granulomas 
(3.1 109/L) (non-specific)
411 F 72 LN, cervical Enlarged LN, No Radiotherapy 2y AND + NMZL Breast cancer
history of CA
5 F 78 Lacrimal gland Enlarged No No + eMZL
lacrimal gland
612 F 84 Spleen Multiple nodules, No W&W 1.4 y Dead Unrelated - FL Colorectal cancer
history of CA
7 M 42 LN, supra-clavicular Enlarged LN No Radiotherapy 1.7y AND - Castleman 
disease
8 M 59 LN, cervical Enlarged LN, No No W&W 5 y AND - Papillary thyroid
history of CA cancer
9 M 58 Intestine Yes No Chemotherapy 1.4 y AND +
SOX11-positive cases
1013 F 42 LN, axillary/ LN, Multiple LN No No Chemotherapy 6 y AND +
inguinal, GIT cervical,
(minimal) iliac
11 F 65 LN Enlarged LN Yes Chemotherapy 0.5 y AND - Granulomas 
(non-specific)
1213 M 65 Appendix Appendicitis W&W 4 y Overt MCL +
13 M 66 LN, pelvic Enlarged LN, Overt MCL ** + Prostate cancer
history of CA
14 M 68 LN, mediastinal Enlarged LN W&W 1y AWD ND
1514 M 70 LN, cervical Enlarged LN No W&W 4 y Overt MCL*** -
16 M 82 Oropharynx Enlarged LT, Yes,  W&W 3y AWD + CLL/SLL
history of CLL both CLL
and MCL
SOX11 not performed
17 M 82 LN Enlarged LN, No, No, Chemotherapy 1.5 AND + CLL/SLL
history of CLL only CLL only CLL
AWD: alive with disease, AND: alive with no evidence of disease, BM: bone marrow, CA: carcinoma, CLL: chronic lymphocytic leukemia/small lymphocytic lymphoma., eMZL: extranodal mar-
ginal zone lymphoma, FL: follicular lymphoma, GIT: gastrointestinal tract, LN: lymph node, LT: lymphoid tissue, MCL:  mantle cell lymphoma, ND: not determined, NMZL: nodal marginal zone
lymphoma, PB: peripheral blood, W&W: watch and wait, y:years.* This case showed CD5 negativity in the first biopsy and also by flow cytometry 8 years later, but CD5-positive monoclonal B
cells were observed in another flow cytometry study 12 years after the initial biopsy. ** This patient had a previous diagnosis of overt MCL, treated with R-CHOP.  He showed an in-situ MCL
lesion 3 years after diagnosis of MCL and being in complete remission. He was followed with a W&W attitude for his in-situ MCL lesion. One year later, he developed a left groin adenopathy
that showed a MCL, classic type, with no other evidence of disease. *** This patient had an “in-situ” MCL lesion which was managed conservatively; 4 years later the patient progressed to
an overt MCL and was treated with chemotherapy. 9-14previously published cases, follow-up updated.
29-84 years) (Table 1). The diagnosis of “in situMCL” was
most often an incidental finding. The biopsies were per-
formed as part of the staging procedure for a previous
diagnosis of carcinoma (5 cases), to evaluate single (5
cases) or multiple (2 cases) enlarged lymph nodes or an
enlarged lacrimal gland (1 case), as part of the diagnostic
evaluation for CLL (2 cases), and in one case an appendec-
tomy had been performed for acute appendicitis. In one
case (intestine sample) the reason is not known. In two
cases the “in situ MCL” lesion was discovered after the
diagnosis of MCL: in one patient it was detected in a ret-
rospective analysis of a previous appendectomy specimen
removed 4 years earlier, and in one patient, it was identi-
fied in a lymphadenectomy obtained at surgery for prosta-
tic carcinoma 3 years after the diagnosis and treatment of
MCL. Immunostains for cyclin D1 were performed as part
of routine immunohistochemical panels in 15 cases, eight
of them to complete the study of other lymphoid lesions,
clinical suspicion of lymphoma in one case, the finding of
atypical cells in the flow cytometry study in one case and
after the prospective or retrospective finding of a classic
MCL in two cases. The most frequent localization of the
“in situ MCL” lesions was nodal; ten cases had a single
enlarged lymph node and two had multiple enlarged
lymph nodes. Five cases were observed in extranodal loca-
tions including small intestine, appendix, lacrimal gland,
spleen and oropharynx. Peripheral blood and/or bone mar-
row involvement was detected in five cases by flow
cytometry or bone marrow biopsy (Table 1). 
Clinical follow-up of at least 1 year was available for 12
patients with “in situMCL” lesions and no diagnosis of overt
MCL at the time the in situ lesion was discovered. Four were
treated with intensive chemotherapy and were alive with
no evidence of disease 0.5, 1.4, 4 and 6 years later; two
patients received involved-field radiotherapy and had no
evidence of disease 1.7 and 2 years later. Eight patients were
managed with watchful waiting: two were alive with no
evidence of disease, 1 and 5 years later, four were alive with
stable disease (atypical circulating cells in the peripheral
blood) 1, 3, 12 and 19 years after the diagnosis, one 84 year-
old patient died of an unrelated cause 1.4 years after the
diagnosis, and one patient developed overt MCL 4 years
after the “in situ MCL” diagnosis. This patient who devel-
oped overt MCL had not been given any treatment at the
time the diagnosis of “in situMCL” was made.
In one patient (case 12), the in situ component was found
in the retrospective examination of an acute appendicitis
specimen that had been obtained 4 years before the diagno-
sis of the overt MCL. In one additional patient (case 13) a
diagnosis of stage IV classic MCL had been made 3 years
earlier; the patient had been treated with R-CHOP and had
achieved a complete remission. The “in situ MCL” lesion
was found in a reactive lymph node obtained as part of the
surgery for a prostatic adenocarcinoma. No evidence of
lymphoma in other sites was observed at the time of the
diagnosis of the “in situ MCL” lesion and a watch-and-wait
attitude was adopted. However, 1 year later the patient
developed left groin adenopathy that showed relapse of
classic MCL with no evidence of disease elsewhere. 
A comparison of the clinical features of the patients with
“in situ MCL” lesions according to SOX11 expression is
summarized in Table 3. The seven patients with SOX11-
positive lesions were five males and two females with a
median age of 66 years (range, 42-82 years). One of the
three patients examined had peripheral blood involvement
and two of six were negative for CD5. Extranodal involve-
ment was seen in three cases. Five patients had a follow-up
of more than 1 year; one received chemotherapy and was
alive after 6 years. The three “in situMCL” lesions associat-
ed with a metachronous MCL were SOX11-positive in
both the in situ lesion and the corresponding overt MCL. 
The nine patients with SOX11-negative “in situ MCL”
lesions were three men and six women with a median age
of 59 years (range, 29-84 years). Differences in the sex
prevalence were not statistically significant. Three patients
had bone marrow involvement, two of whom also had
peripheral blood involvement and six of the nine were neg-
ative for CD5. Extranodal involvement was seen in three
cases. Eight patients had follow-up of more than 1 year.
Three of them were treated, one patient received aggressive
chemotherapy and was alive after 1.4 years and two
patients received local radiotherapy and were alive after 1.7
and 2 years. Five patients were not treated and had a medi-
an survival of 5 years (range, 1-19.5 years); one of these
patients died of unrelated causes 1.4 years after the diagno-
sis. None of the patients developed overt MCL.
In situ mantle cell lymphoma
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Table 2. Clinical features, follow-up and histopathological findings in MCL with mantle zone growth pattern.
Case Sex Age Site of Disease BM PB Management Follow-up Status CD5 Other 
N. diagnosis progression associated 
pathology
SOX11-negative case
18 F 56 LN cervical BM Yes Yes (4,9¥109/L) W&W 6 y AWD (PB) +
SOX11-positive cases
19 M 65 Gallbladder No No No W&W 1 y Dead unrelated - Colorectal
cancer
20 M 77 Waldeyer ring Abdominal Yes Yes W&W* 2.5 y AWD +
LN,spleen
21 M 54 Tonsil LN, cervical Yes No Chemo-therapy 6y AWD +
22 M 36 LN, mediastinal, cervical No No No W&W 2 y AWD (LN) + Sarcoidosis
23 M 71 LN cervical LN, axillary Chemo-therapy +
AWD: alive with disease, BM: bone marrow, LN: lymph node, MCL: mantle cell lymphoma, PB: peripheral blood involvement, W&W: watch and wait, y:years.* This patient started
immunotherapy 2.5 years after the initial diagnosis.
Clinical features of mantle cell lymphoma 
with a mantle zone growth pattern
Five of the six patients with a MCL with a mantle zone
pattern were male with a median age of 60 years (range,
36-78 years). Five of the six cases were SOX11-positive
and one was SOX11-negative. CD5 was expressed in five
cases and was negative in one. Four patients showed evi-
dence of disseminated disease at diagnosis, three of them
had bone marrow involvement, two with peripheral
blood involvement, and one had cervical and axillary lym-
phadenopathy. Two patients were considered to have
localized lesions, one in the gallbladder and the other in a
cervical lymph node. This latter patient had sarcoidosis
and mediastinal lymphadenopathy. Two patients with
clinical evidence of dissemination to other lymph nodes
at diagnosis were treated with chemotherapy; both cases
were SOX11-positive. Follow-up data were available for
one of them, who was alive with disease 6 years after
diagnosis. Four patients were managed with a watchful
waiting approach; three were SOX11-positive and one
was negative. The single patient with a SOX11-negative
MCL had stable leukemic disease and was alive 6 years
after diagnosis. One of the SOX11-positive cases devel-
oped disease progression 2 years after the diagnosis and
was treated with immunotherapy. The other two SOX11-
positive cases were the patient with sarcoidosis who had
stable mediastinal lymphadenopathy after 2 years of fol-
low-up, and the other patient died of unrelated causes 1
year after diagnosis.
Discussion
In this study we have recognized two clinically and bio-
logically distinct types of lesions characterized by cyclin
D1-positive cells mostly limited to the mantle zones of
reactive follicles. The cases we believe belong in the cate-
gory of “in situMCL” lesions had relatively few cyclin D1-
positive cells restricted to the mantle area and concomi-
tant or subsequent overt MCL was uncommon. The sec-
ond group, which is best considered as MCL with a man-
tle zone growth pattern, had more extensive cyclin D1-
positive cells with focal extension into the interfollicular
areas and a more frequent association with conventional
MCL without a mantle zone pattern. This suggests that
the “in situMCL” lesions may correspond to an early step
in the lymphomagenesis of MCL, whereas MCL with a
mantle zone growth pattern represent partial or early
involvement by lymphoma.
Recent studies have found clonal B cells carrying the
t(14;18) translocation restricted to the germinal centers in
an otherwise reactive lymph node.15,16 These lesions were
interpreted as an early step in the lymphomagenesis of
follicular lymphoma, and have been termed FLIS. They
may correspond to the circulating cells carrying the
t(14;18) found in many normal individuals, and appear to
have a very low malignant potential. The “in situ MCL”
lesions investigated in this and other studies of individual
cases14,23,30 may correspond to a similar phenomenon. We
detected the t(11;14) translocations in the eight “in situ
MCL” lesions studied and in one of them we confirmed
that the translocation was present in the cyclin D1-posi-
tive cells. These observations support the genetic relation-
ship of these limited lesions to MCL and rule out the pos-
sibility that cyclin D1 is overexpressed by other mecha-
nisms as may be occasionally seen in cells of the prolifer-
ation centers in CLL.24 Clones carrying the t(11;14)
translocation may be found at very low levels in the
peripheral blood of healthy individuals using very sensi-
tive methods.25 These clones persist over long periods and
in some cases may even expand. Although there is no evi-
dence that these clones progress to overt lymphoma, they
may represent a very early event in MCL lymphomagen-
esis. The “in situMCL” lesions observed in this study may
correspond to the tissue counterpart of these circulating
clones. 
To evaluate the frequency of “in situ MCL” lesions, we
stained 100 consecutive specimens of reactive follicular
hyperplasia in adults for cyclin D1 and none of them
showed positive cells, indicating that this situation must
be uncommon in routine practice. Therefore, the use of
cyclin D1 staining in the context of a reactive lymph node
does not seem to be necessary. We also stained the same
cohort for BCL2 and found two cases with FLIS. These
findings parallel in part the observation of clones carrying
the t(11;14) and the t(14;18) translocation in the blood of
healthy individuals using highly sensitive methods. The
t(11;14) was detected only in 7% of individuals whereas
the t(14;18) was found in up to 71% of healthy people.25-
27 Interestingly, almost all healthy individuals carrying the
t(11;14) also had clones with the t(14;18), and clones with
this translocation were also found in patients with overt
MCL.25 The concomitant identification of clones with
both translocations in the same individual may corre-
spond at a molecular level to the frequent association of
“in situMCL” lesions with follicular lymphoma and other
indolent small B-cell lymphomas observed in this study.
This phenomenon is also seen in FLIS,15,16,28 suggesting
that these patients may have a certain susceptibility to
develop and expand aberrant B-cell clones.   
Most patients with “in situMCL” lesions presented with
a localized enlarged lymph node or extranodal lymphoid
tissue. However, six of 17 patients had evidence of more
widespread disease. Five patients had bone marrow
and/or peripheral blood involvement, and a sixth patient
had “in situ MCL” lesions simultaneously in an axillary
and inguinal lymph node, as well as minimal infiltration
a. Carvajal-Cuenca et al.
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Table 3. Relationship between SOX11 expression and clinicopatholog-
ical aspects of “in situ MCL” lesions and MCL with mantle zone growth
pattern (MZP).
“in situ MCL” MCL with MZP
n=16 n=6
SOX11 + SOX11 – SOX11 + SOX11 –
7 (44%) 9 (56%) 5 (83%) 1 (17%)
Male:Female 5:2 3:6 5:0 0:1
Median age (range) 66y (42-82) 59y (29-84) 61y (36-78) 56y
PB/BM + 1/3 3/8 2/4 1/1
CD5 - 2/5 6/9 1/5 0/1
MCL without MZP 3* 0 3 0
Stable-No Disease 3/5 7/7 1/4 1/1
>1 year
Treated 1 (6y) 2 (1.4, 2y)
Untreated 2 (1, 3y) 4 (1-19.5y) 1 (2y) 1 (6y)
Dead of unrelated cause 1 (1.4y) 1 (1y)
BM: bone marrow, n: number of cases, PB: peripheral blood involvement, y: years. *In
two of these patients the "in situ" MCL component was recognized after the diagno-
sis of overt MCL.
of a gastric biopsy by cyclin D1-positive cells.13 The clini-
cal  significance of these disseminated cells is uncertain
because  their numbers were always limited in all loca-
tions and the evolution of disease in three of these
patients was very indolent with a stable presence of atyp-
ical cells in the peripheral blood for more than 3, 12 and
19 years without any antineoplastic treatment.9,10 The
patient with more than one lymph node involved and
minimal gastric infiltration was alive with no evidence of
disease 6 years later but he had been treated with high-
dose immunochemotherapy and stem cell transplanta-
tion. The apparent dissemination in these cases may rep-
resent the normal circulating nature of lymphoid cells
rather than an indication of clinically significant malig-
nant potential. Dissemination of FLIS in the absence of
more overt lymphoma is also well-recognized.12,15,16,28 The
indolent behavior of the “in situMCL” lesions is also rein-
forced by the evolution of four other patients managed
with watchful waiting who did not have progression of
disease 1, 1, 1.4 and 5 years after diagnosis, although the
third died of an unrelated cause at the age of 84.12 Six
patients treated with local radiotherapy or chemotherapy
were also alive and without evidence of disease 0.5 to 6
years later (median 1.6 years).11,13,14
Only three patients with “in situMCL” lesions had overt
MCL. In two cases the in situ lesion was discovered after
the diagnosis of the MCL. In one patient it was detected
in a retrospective analysis of a previous appendectomy
specimen removed 4 years earlier.13 In the second patient,
the “in situMCL” lesion was identified in a lymphadenec-
tomy obtained at surgery for prostatic carcinoma 3 years
after the diagnosis and treatment of MCL. The persist-
ence of cyclin D1-positive cells in the mantle zones of a
MCL patient in apparent complete remission highlights
the relevance of the mantle zone as a microenvironment
favoring the survival of cells with the t(11;14) transloca-
tion, not only in early steps of the disease, but also as a
potential sanctuary for chemotherapy-resistant cells. This
patient relapsed with overt MCL 1 year later. Only one
patient without overt MCL at the time of the diagnosis of
the in situ lesion developed an overt MCL 4 years later.
The follow-up of the patients in our study suggests that
most patients with “in situMCL” lesions do not develop an
overt MCL for long periods of time (1 to 19.5 years), even
without any treatment. However, in some cases the lesion
may evolve into overt MCL. This evolution to MCL is
consistent with recent observations by Racke et al., pub-
lished in abstract form, in which all seven MCL patients
examined had an “in situ MCL” lesion in reactive lymph
nodes obtained between 2 and 15 years (median 8 years)
prior to the diagnosis of the overt lymphoma.29 A similar
case has been recently reported in which an in situ lesion
was found in a gastrointestinal tract biopsy 2 years before
the diagnosis of overt intestinal MCL.30 This long latency
period prior to the development of MCL has also been
highlighted by the diagnosis of a MCL 12 years after an
allogenic bone marrow transplantation occurring simulta-
neously in the respective recipient and donor and corre-
sponding to the same neoplastic clone in both patients.31
Although MCL with a mantle zone growth pattern was
not always associated with conventional MCL with
nodular or diffuse patterns, four of the six patients devel-
oped MCL with more extensive infiltration. Three
patients, two with bone marrow involvement, showed
lymphadenopathy at other sites; two were treated with
chemotherapy, whereas one patient with peripheral
blood and bone marrow involvement at the time of diag-
nosis was not treated and developed abdominal lym-
phadenopathy 1 year later. One patient with bone mar-
row dissemination followed with watchful waiting had
stable disease in the peripheral blood 6 years after the
diagnosis and one untreated patient died of an unrelated
cause 1 year after the diagnosis. 
These findings highlight the low malignant potential of
the “in situ MCL” lesions which is similar to that of FLIS
and raises the question of maintaining the term “lym-
phoma” for these lesions.15,16 In contrast, MCL with a
mantle zone pattern appears to correspond to early
involvement by conventional MCL similar to partial
involvement of a lymph node by follicular lymphoma.16,32
A recent Workshop of the European Association for
Hematopathology and the Society for Hematopathology
(Uppsala, Sweden, September 2010) proposed the alterna-
tive terms of “in situ MCL-like B cells” and “in situ FL-like
B cells of uncertain significance” to avoid overdiagnosis
and overtreatment of these individuals.33 These recom-
mendations are parallel to the use of monoclonal gam-
mopathy of uncertain significance and monoclonal B-cell
lymphocytosis for potentially premalignant phases of
plasma cell myeloma and CLL, respectively. 
SOX11 is a specific marker of MCL expressed in 78-
93% of these tumors.6,18,20 In a recent study, a group of
MCL with a very indolent clinical behavior and managed
without any treatment for more than 2 years were con-
sistently SOX11-negative. The expression of this bio-
marker was less common in the “in situ MCL” lesions
(44%) than in the MCL with a mantle zone pattern (5 of
6 cases, 83%), which is a similar proportion to that
observed in other overt MCL. Interestingly, the only
patient with a SOX11-negative MCL with a mantle zone
pattern had very stable disease for 6 years without treat-
ment. Although not statistically significant, it is intrigu-
ing that the SOX11-negative “in situ MCL” lesions were
mainly found in women (67%) whereas SOX11- positive
“in situ MCL” lesions and mantle zone pattern lesions
were more common in men (71% and 83%, respective-
ly). Both SOX11-negative and -positive “in situ MCL”
lesions had a very indolent behavior. However, the
tumors in the three patients who had overt MCL either
before or after the diagnosis of “in situ MCL were
SOX11-positive in both the “in situ MCL” lesion and the
overt MCL. The expression of SOX11 in some “in situ
MCL” lesions, the progression of SOX11-positive “in situ
MCL” lesion to an overt MCL, and the higher number of
cases of SOX11-positive MCL with a mantle zone pat-
tern indicate that SOX11 is already differentially
expressed early in the development of “in situ MCL”
lesions and suggest that lesions expressing SOX11 may
have a greater tendency to progress. 
In conclusion, our data suggest that cases diagnosed as
“in situ mantle cell lymphoma” include two distinct situa-
tions with different clinical impact. Some cases are overt
MCL with a mantle zone growth pattern that may have
disseminated disease at diagnosis, although some cases
may also follow a relatively indolent course. In these
cases, a diagnosis of MCL should be made, with a com-
ment regarding the pattern. Other cases, in which the
nodal architecture is preserved and cyclin D1-positive
cells are restricted to mantle zones of otherwise normal-
appearing follicles, appear to have a very low, but still def-
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inite risk of progression to overt MCL. In these cases we
suggest that a diagnosis of “in situ involvement by mantle
cell lymphoma-like cells” should be made, with a note
indicating that this does not constitute a diagnosis of lym-
phoma, and that treatment should not be undertaken
based solely on the basis of this finding. In such cases,
surveillance of the patients and evaluation for the pres-
ence of progressive disease should be considered.
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